Home / Hims & Hers: EU Expansion, Q1 Earnings, & Strategies

Hims & Hers: EU Expansion, Q1 Earnings, & Strategies

By: Jasmin Espinas
June 9, 2025

Hims & Hers is expanding in direct-to-consumer telehealth, offering prescription treatments, personal care products, and mental health services. It continues to grow its subscriber base while competing with both startups and larger healthcare platforms.

Recent moves suggest a shift in pace and focus. The company’s EU expansion, Q1 2025 earnings report, collaboration with Novo Nordisk, and new executive appointments reflect how it is approaching expansion, operations, and product access with more precision.

Latest News: Hims & Hers to Acquire ZAVA for EU Market Expansion

On June 3, Hims & Hers announced its agreement to acquire ZAVA, a digital healthcare provider with operations across the UK and several European markets.

Big news: We’ve agreed to acquire ZAVA, a leading digital health platform in Europe. 🌍

We are actively building a global healthcare reality where convenient, transparent care rooted in customer choice is accessible to everyone. Today’s news is a meaningful step forward,… pic.twitter.com/WTA2d293Ov

— hims (@wearehims) June 3, 2025

The move will expand Hims & Hers into Germany, France, and Ireland, with more markets expected to follow.

At the same time, Hims & Hers plans to launch its brand in these countries while using ZAVA’s infrastructure to support operations.

ZAVA’s team completed over 2.3 million consultations in 2024 and currently serves more than 1.3 million active users. This scale gives Hims & Hers an established base for entry and immediate reach.

In addition, the European rollout will include localized services, with care offered by providers based in the UK, Germany, and France.

Core focus areas will include dermatology, mental health, sexual health, and weight loss. Hims & Hers also expects the acquisition to strengthen its international business and increase earnings by 2026.

Hims & Hers Q1 2025 Revenue Beats Expectations

Hims & Hers reported $586 million in revenue for Q1 2025, more than double the same quarter last year.

Meanwhile, net income reached $49.5 million, and adjusted EBITDA reached $91.1 million. Paid subscribers increased to 2.4 million, up 38% year-over-year.

The company reaffirmed its full-year revenue forecast of $2.3 to $2.4 billion and raised its adjusted EBITDA guidance to $295 to $335 million.

It also introduced 2030 targets, aiming for at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA.

For Q2 2025, Hims & Hers expects revenue between $530 and $550 million and adjusted EBITDA between $65 and $75 million, reflecting a margin of up to 14%.

CEO Andrew Dudum attributed the growth to expanded access and stronger patient engagement.

Hims & Hers Partners With Novo Nordisk on Wegovy Access

On April 29, Hims & Hers announced a long-term agreement with Novo Nordisk to expand access to obesity treatment.

This collaboration introduces Wegovy prescriptions through NovoCare® Pharmacy, now available on the Hims & Hers platform.

The initial rollout offers all Wegovy dose strengths bundled with a Hims & Hers membership, which includes round-the-clock clinical access, nutrition support, and ongoing care.

This integrated package is now live and aims to streamline how patients begin and manage treatment.

Both companies are also working on broader plans that combine Novo Nordisk’s medications with Hims & Hers’ telehealth model to support more patients at lower cost, with more consistent clinical oversight.

Hims & Hers Appoints New CTO and COO to Drive AI and Global Operations

Hims & Hers appointed Mo Elshenawy as Chief Technology Officer on May 8.

Elshenawy brings over 20 years of experience in AI infrastructure and product engineering.

ameborder=”0″ allowfullscreen=”allowfullscreen”>

Before joining Hims & Hers, he served as President and CTO at Cruise, where he helped lead the company’s driverless rideshare program in San Francisco through technical and regulatory hurdles.

Earlier, at Amazon, he directed global engineering for its ReCommerce division and built retail analytics platforms responsible for significant revenue growth. He holds more than 10 patents in AI, robotics, and automation.

Separately, on May 5, the company named Nader Kabbani as Chief Operations Officer. He will lead global logistics and support functions as Hims & Hers scales access across new regions and verticals.

At Amazon, he oversaw the acquisition of PillPack and helped launch Amazon Pharmacy, in addition to building core operations for Kindle, Amazon Logistics, Prime Video, and other services.

He also managed Amazon’s COVID-19 vaccination program for over one million people.

Kabbani later held senior roles at Flexport and Symbotic, focusing on supply chain automation and AI-driven retail logistics.

Conclusion

Hims & Hers is positioning itself as more than a telehealth provider.

As it expands into new markets and product categories, the company appears committed to balancing access with operational discipline.

If current trends continue, Hims & Hers could emerge as one of the few direct-to-consumer healthcare companies with both reach and profitability in view.

Subscribe to Financial Daily Update today to stay informed with the latest on Hims & Hers and for focused reporting on business, finance, and health tech.